Loading...

Ultragenyx Pharmaceutical

DB:UP0
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
UP0
DB
$4B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The last earnings update was 61 days ago. More info.


Add to Portfolio Compare Print
  • Ultragenyx Pharmaceutical has significant price volatility in the past 3 months.
UP0 Share Price and Events
7 Day Returns
-11.3%
DB:UP0
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
29.1%
DB:UP0
-10.2%
DE Biotechs
-6%
DE Market
UP0 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ultragenyx Pharmaceutical (UP0) -11.3% -5.6% 23.2% 29.1% -15.5% 123.7%
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • UP0 outperformed the Biotechs industry which returned -10.2% over the past year.
  • UP0 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
UP0
Industry
5yr Volatility vs Market
Related Companies

UP0 Value

 Is Ultragenyx Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Ultragenyx Pharmaceutical. This is due to cash flow or dividend data being unavailable. The share price is €56.69.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ultragenyx Pharmaceutical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ultragenyx Pharmaceutical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:UP0 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.97
NasdaqGS:RARE Share Price ** NasdaqGS (2019-04-18) in USD $65.36
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ultragenyx Pharmaceutical.

DB:UP0 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:RARE Share Price ÷ EPS (both in USD)

= 65.36 ÷ -3.97

-16.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ultragenyx Pharmaceutical is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Ultragenyx Pharmaceutical is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Ultragenyx Pharmaceutical's expected growth come at a high price?
Raw Data
DB:UP0 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -16.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts
34.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Ultragenyx Pharmaceutical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ultragenyx Pharmaceutical's assets?
Raw Data
DB:UP0 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $11.97
NasdaqGS:RARE Share Price * NasdaqGS (2019-04-18) in USD $65.36
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:UP0 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:RARE Share Price ÷ Book Value per Share (both in USD)

= 65.36 ÷ 11.97

5.46x

* Primary Listing of Ultragenyx Pharmaceutical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ultragenyx Pharmaceutical is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Ultragenyx Pharmaceutical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Ultragenyx Pharmaceutical has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

UP0 Future Performance

 How is Ultragenyx Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 17 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ultragenyx Pharmaceutical expected to grow at an attractive rate?
  • Ultragenyx Pharmaceutical's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Ultragenyx Pharmaceutical's earnings growth is expected to exceed the Germany market average.
  • Ultragenyx Pharmaceutical's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:UP0 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:UP0 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts 34.6%
DB:UP0 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 17 Analysts 40.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:UP0 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:UP0 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 773 176 180 7
2022-12-31 575 38 -46 7
2021-12-31 368 -122 -182 12
2020-12-31 215 -210 -275 15
2019-12-31 101 -277 -352 17
DB:UP0 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 51 -291 -198
2018-09-30 38 -317 -192
2018-06-30 26 -309 -183
2018-03-31 13 -282 -204
2017-12-31 3 -254 -302
2017-09-30 0 -220 -292
2017-06-30 0 -186 -277
2017-03-31 0 -177 -261
2016-12-31 0 -161 -246
2016-09-30 0 -154 -230
2016-06-30 0 -156 -204
2016-03-31 -133 -177

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ultragenyx Pharmaceutical's earnings are expected to grow significantly at over 20% yearly.
  • Ultragenyx Pharmaceutical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:UP0 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below

All data from Ultragenyx Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:UP0 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.93 6.68 0.15 7.00
2022-12-31 -0.78 -0.05 -2.08 5.00
2021-12-31 -3.05 -1.46 -5.45 12.00
2020-12-31 -4.86 -3.77 -7.06 15.00
2019-12-31 -6.59 -5.63 -7.37 18.00
DB:UP0 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.97
2018-09-30 -4.00
2018-06-30 -3.99
2018-03-31 -4.62
2017-12-31 -7.12
2017-09-30 -6.97
2017-06-30 -6.74
2017-03-31 -6.49
2016-12-31 -6.21
2016-09-30 -5.88
2016-06-30 -5.26
2016-03-31 -4.65

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Ultragenyx Pharmaceutical will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Ultragenyx Pharmaceutical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ultragenyx Pharmaceutical has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

UP0 Past Performance

  How has Ultragenyx Pharmaceutical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ultragenyx Pharmaceutical's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ultragenyx Pharmaceutical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Ultragenyx Pharmaceutical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ultragenyx Pharmaceutical's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Ultragenyx Pharmaceutical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ultragenyx Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:UP0 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 51.50 -197.61 127.72
2018-09-30 37.65 -191.52 124.97
2018-06-30 26.08 -183.43 117.37
2018-03-31 13.29 -203.60 106.66
2017-12-31 2.61 -302.14 93.91
2017-09-30 0.20 -291.70 82.00
2017-06-30 0.12 -277.38 75.68 -83.75
2017-03-31 0.13 -261.41 70.41 -40.42
2016-12-31 0.13 -245.87 64.94
2016-09-30 0.13 -229.81 56.72 44.57
2016-06-30 0.02 -204.13 49.77 158.02
2016-03-31 -177.00 42.07 137.79
2015-12-31 -145.62 33.00
2015-09-30 -107.14 24.83 83.69
2015-06-30 -83.75 17.58 66.84
2015-03-31 -67.55 12.96 54.98
2014-12-31 -64.61 10.81 45.97
2014-09-30 -66.54 8.71 40.65
2014-06-30 -63.28 6.73 34.56
2014-03-31 -60.52 5.35 30.52
2013-12-31 -50.29 4.45 27.83
2013-09-30 -38.44 4.03 23.40
2012-12-31 -19.56 3.34 12.64

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ultragenyx Pharmaceutical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Ultragenyx Pharmaceutical has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Ultragenyx Pharmaceutical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ultragenyx Pharmaceutical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ultragenyx Pharmaceutical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

UP0 Health

 How is Ultragenyx Pharmaceutical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ultragenyx Pharmaceutical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ultragenyx Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ultragenyx Pharmaceutical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ultragenyx Pharmaceutical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Ultragenyx Pharmaceutical has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ultragenyx Pharmaceutical Company Filings, last reported 3 months ago.

DB:UP0 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 608.91 0.00 459.71
2018-09-30 662.60 0.00 503.10
2018-06-30 703.97 0.00 547.13
2018-03-31 723.66 0.00 541.35
2017-12-31 383.45 0.00 234.49
2017-09-30 365.56 0.00 371.07
2017-06-30 429.45 0.00 399.65
2017-03-31 488.48 0.00 425.19
2016-12-31 473.97 0.00 380.15
2016-09-30 455.89 0.00 396.43
2016-06-30 443.90 0.00 391.80
2016-03-31 489.82 0.00 411.86
2015-12-31 531.09 0.00 437.00
2015-09-30 576.76 0.00 448.38
2015-06-30 319.28 0.00 326.03
2015-03-31 341.12 0.00 342.57
2014-12-31 184.95 0.00 187.49
2014-09-30 199.33 0.00 201.19
2014-06-30 153.08 0.00 153.27
2014-03-31 165.71 0.00 165.40
2013-12-31 53.53 0.00 53.38
2013-09-30 58.47 0.00 63.66
2012-12-31 84.86 0.00 86.19
  • Ultragenyx Pharmaceutical has no debt.
  • Ultragenyx Pharmaceutical has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Ultragenyx Pharmaceutical has sufficient cash runway for 1.6 years based on current free cash flow.
  • Ultragenyx Pharmaceutical has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 32% each year.
X
Financial health checks
We assess Ultragenyx Pharmaceutical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ultragenyx Pharmaceutical has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

UP0 Dividends

 What is Ultragenyx Pharmaceutical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ultragenyx Pharmaceutical dividends. Estimated to be 0% next year.
If you bought €2,000 of Ultragenyx Pharmaceutical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ultragenyx Pharmaceutical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ultragenyx Pharmaceutical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:UP0 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:UP0 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 3.00
2020-12-31 0.00 3.00
2019-12-31 0.00 4.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ultragenyx Pharmaceutical has not reported any payouts.
  • Unable to verify if Ultragenyx Pharmaceutical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ultragenyx Pharmaceutical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ultragenyx Pharmaceutical has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Ultragenyx Pharmaceutical's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Ultragenyx Pharmaceutical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ultragenyx Pharmaceutical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ultragenyx Pharmaceutical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

UP0 Management

 What is the CEO of Ultragenyx Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Emil Kakkis
COMPENSATION $6,684,899
AGE 58
TENURE AS CEO 9 years
CEO Bio

Dr. Emil D. Kakkis, MD, Ph.D. has been the Chief Executive Officer and President of Ultragenyx Pharmaceutical Inc. since April 2010. Dr. Kakkis founded Ultragenyx in April 2010. He served as Scientific Advisor of Tarix Pharmaceuticals LTD. and Edimer Pharmaceuticals Inc. Prior to Ultragenyx, Dr. Kakkis served from September 1998 to February 2009 in various executive capacities at BioMarin Pharmaceutical Inc. He served as an Advisor of BioMarin Pharmaceutical Inc. since March 2009. Dr. Kakkis served as a development consultant to BioMarin from 2009 through 2010. He has specific expert knowledge in genetics and rare diseases and has operational experience in the life sciences sector. He is best known for his work over 18 years to develop novel treatments for rare disorders. He began his work developing an enzyme replacement therapy (Aldurazyme ) for the rare disorder MPS I, with minimal funding and support. He served as Chief Medical Officer of BioMarin Pharmaceutical Inc. from January 2006 to February 2009 and also served as its Senior Vice President. Dr. Kakkis served as Senior Vice President of Business Operations at BioMarin Pharmaceutical Inc. since January 2002 and Senior Vice President of Global Commercial Development. Dr. Kakkis served as a Vice President of BioMarin since September 1998. During his tenure at BioMarin, Dr. Kakkis guided the development and approval of two more treatments for rare disorders, MPS VI and PKU and has contributed to the initiation of 7 other treatment programs for rare disorders, three of which are in clinical development. After 11 years at BioMarin, Dr. Kakkis left industry to initiate an effort to improve the regulatory and clinical development process for rare diseases. He has been Member of Scientific and Technical Advisory Board of imension Therapeutics, Inc. since October 31, 2013. He serves as a Scientific Advisor at Dimension Therapeutics, Inc. He joined BioMarin in 1998 and left in 2009. In early 2009, Dr. Kakkis launched Kakkis EveryLife Foundation in 2009 and funded to accelerate biotech innovation for rare diseases and serves as its President. Dr. Kakkis is a trustee of Jenny Soriano Living Trust. From 1993 to August 1998, Dr. Kakkis served as an Assistant Professor of Pediatrics at the Harbor-UCLA Medical Center, Division of Genetics, Department of Pediatrics and initiated the enzyme therapy program for MPS I. He has been a Director of Ultragenyx Pharmaceutical Inc. since its inception in April 2010. He is the Author of numerous published articles and abstracts on MPS I and alpha-L-iduronidase. He is a Trustee of Jenny Soriano Living Trust. Dr. Kakkis holds a B.A. in Biology from Pomona College, magna cum laude and received combined MD and PhD degrees from the UCLA School of Medicine’s Medical Scientist Training Program and received the Bogen prize for his research. He is board certified in both Pediatrics and Medical Genetics. He completed a Pediatrics residency and Medical Genetics Training Fellowship at Harbor- UCLA Medical Center.

CEO Compensation
  • Emil's compensation has increased whilst company is loss making.
  • Emil's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Ultragenyx Pharmaceutical management team in years:

4.5
Average Tenure
52.5
Average Age
  • The tenure for the Ultragenyx Pharmaceutical management team is about average.
Management Team

Emil Kakkis

TITLE
President
COMPENSATION
$7M
AGE
58
TENURE
9 yrs

Shalini Sharp

TITLE
CFO & Executive VP
COMPENSATION
$3M
AGE
43
TENURE
6.9 yrs

Tom Kassberg

TITLE
Chief Business Officer & Executive VP
COMPENSATION
$2M
AGE
58
TENURE
7.4 yrs

John Pinion

TITLE
Chief Quality Operations Officer & Executive VP of Translational Sciences
COMPENSATION
$2M
AGE
52
TENURE
3.8 yrs

Vlad Hogenhuis

TITLE
Chief Operating Officer
TENURE
0.6 yrs

Theodore Huizenga

TITLE
VP, Corporate Controller & Principal Accounting Officer
AGE
47
TENURE
5.1 yrs

Dennis Huang

TITLE
Chief Technical Operations Officer & Executive VP
COMPENSATION
$4M
AGE
53
TENURE
3.9 yrs

Danielle Keatley

TITLE
Senior Director of Investor Relations & Corporate Communications

Karah Parschauer

TITLE
General Counsel & Executive VP
COMPENSATION
$3M
AGE
40
TENURE
2.8 yrs

Cordelia Leonard

TITLE
Senior Vice President of Regulatory Affairs
AGE
58
Board of Directors Tenure

Average tenure and age of the Ultragenyx Pharmaceutical board of directors in years:

4.2
Average Tenure
58
Average Age
  • The tenure for the Ultragenyx Pharmaceutical board of directors is about average.
Board of Directors

Dan Welch

TITLE
Non-Executive Chairman
COMPENSATION
$359K
AGE
60
TENURE
3.8 yrs

Emil Kakkis

TITLE
President
COMPENSATION
$7M
AGE
58
TENURE
9 yrs

Bill Aliski

TITLE
Director
COMPENSATION
$341K
AGE
72
TENURE
8.3 yrs

Matt Fust

TITLE
Director
COMPENSATION
$346K
AGE
53
TENURE
5.3 yrs

Lars Ekman

TITLE
Director
COMPENSATION
$328K
AGE
68
TENURE
3.1 yrs

Clay Siegall

TITLE
Director
COMPENSATION
$330K
AGE
57
TENURE
5.3 yrs

Mike Narachi

TITLE
Independent Director
COMPENSATION
$331K
AGE
59
TENURE
4.2 yrs

Deborah Dunsire

TITLE
Independent Director
COMPENSATION
$820K
AGE
56
TENURE
2 yrs

Shehnaaz Suliman

TITLE
Independent Director
AGE
46
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • Ultragenyx Pharmaceutical insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
17. Apr 19 Sell Emil Kakkis Individual 05. Mar 19 05. Mar 19 -2,890 €57.99 €-167,577
17. Apr 19 Sell Thomas Kassberg Individual 05. Mar 19 05. Mar 19 -832 €57.99 €-48,244
17. Apr 19 Sell Theodore Huizenga Individual 05. Mar 19 05. Mar 19 -254 €57.99 €-14,728
17. Apr 19 Sell Dennis Huang Individual 05. Mar 19 05. Mar 19 -626 €57.99 €-36,299
17. Apr 19 Sell John Pinion Individual 05. Mar 19 05. Mar 19 -722 €57.99 €-41,865
17. Apr 19 Sell Karah Parschauer Individual 05. Mar 19 05. Mar 19 -886 €57.99 €-51,375
17. Apr 19 Sell Shalini Sharp Individual 05. Mar 19 05. Mar 19 -1,012 €57.99 €-58,681
08. Aug 18 Sell William Aliski Individual 08. Aug 18 08. Aug 18 -3,750 €66.07 €-247,746
13. Jun 18 Sell Theodore Huizenga Individual 13. Jun 18 13. Jun 18 -1,338 €65.36 €-87,456
X
Management checks
We assess Ultragenyx Pharmaceutical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ultragenyx Pharmaceutical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

UP0 News

Simply Wall St News

UP0 Company Info

Description

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing DTX701 that is in preclinical development for Wilson disease; UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.

Details
Name: Ultragenyx Pharmaceutical Inc.
UP0
Exchange: DB
Founded: 2010
$3,268,349,428
57,112,291
Website: http://www.ultragenyx.com
Address: Ultragenyx Pharmaceutical Inc.
60 Leveroni Court,
Novato,
California, 94949,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS RARE Common Stock Nasdaq Global Select US USD 31. Jan 2014
DB UP0 Common Stock Deutsche Boerse AG DE EUR 31. Jan 2014
LSE 0LIF Common Stock London Stock Exchange GB USD 31. Jan 2014
Number of employees
Current staff
Staff numbers
610
Ultragenyx Pharmaceutical employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:02
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/22
Last earnings filing: 2019/02/20
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.